


Under the Paperwork Reduction Act of 95, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

FEE TRANSMITTAL
for FY 2001

Patent fees are subject to annual revision.



Complete if Known

#1 ATTACe

Application Number	09/525,041
Filing Date	March 14, 2000
First Named Inventor	Soppet, et al.
Examiner Name	Monshipouri, M.
Group Art Unit	1652
Attorney Docket Number	PF178D2

Total amount of payment (\$2,280.00)

METHOD OF PAYMENT (CHECK ONE)

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

08-3425

Deposit Account Number

Deposit Account Human Genome Sciences, Inc.
Name Charge Any Additional Fee Required
Under 37 CFR §§ 1.16 and 1.17 Applicant claims small entity status

See 37 CFR 1.27

2. Payment Enclosed: Check Credit Card Money Order Other

Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee	Entity Fee	Small Entity Fee	Entity Fee	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

Subtotal (1) \$

2. EXTRA CLAIM FEES

Total claims	114	- 20**	94	Fee from below	Fee Paid
Indep. claims	10	- 3**	7	84.00	\$ 588.00

Multiple Dependent					

Large Entity Fee	Entity Fee	Small Entity Fee	Entity Fee	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
108	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

Subtotal (2) (\$2,280.00)

Submitted By

Name (Print/Type) Jonathan L. Klein

Signature:

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

3. ADDITIONAL FEES		FEE CALCULATION (CONTINUED)	
Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)
105	130	205	65
127	50	227	25
139	130	139	130
147	2,520	147	2,520
112	920	112	920
113	1,840	113	1,840
115	110	215	55
116	390	216	195
117	890	217	445
118	1,390	218	695
128	1,890	228	945
119	310	219	155
120	310	220	155
121	270	221	135
138	1,510	138	1,510
140	110	240	55
141	1,240	241	620
142	1,240	242	620
143	440	243	220
144	600	244	300
122	130	122	130
123	50	123	50
126	240	126	240
581	40	481	40
146	710	246	355
149	710	249	355
179	710	279	355
169	190	169	900
Other fee (specify):			
Other fee (specify):			
*Reduced by Basic Filing Fee Paid			
Subtotal (3) \$			
10/15/2001 TJOHNS04 00000001 083425 09525041			
01 FC:103 1692.00 CH			
02 FC:102 588.00 CH			
Complete (if applicable)			
Registration No.: 41,119 Telephone 301-251-6015			
Date October 9, 2001			

RECEIVED
PTO
OCT 11 2001

#81508
10/13/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Soppet, et al.

Serial No.: 09/525,041

Filed: March 14, 2000

Title: Colon Specific Gene and Protein

Group Art Unit: 1652

Examiner: Monshipouri, M.

Attorney Docket No.: PF178D2

RECEIVED
OCT 11 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AP listed on the two attached Forms PTO/SB/08. Copies of references AD, AE, AF, AO, and AP are enclosed. References AD and AF were cited to Applicants in a Supplemental European Search Report (reference AO) in connection with a corresponding foreign application. Reference AE is a published PCT Application corresponding to the present application.

Copies of references AB, AC, AG, AH, AI, AJ, and AK, and AN were submitted by Applicants or cited by the Examiner in connection with U.S. Patent Application Serial No. 08/468,413 filed June 6, 1995, now issued as U.S. Patent Number 5,861,494, to which the instant application claims priority under 35 U.S.C. § 120. Additionally, copies of references AA, AL and AM were submitted by Applicants or cited by the Examiner in connection with related U.S. Patent Application Serial No. 09/162,508 filed September 29, 1998, now issued as U.S. Patent Number 6,080,722, to which the instant application claims priority under

35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the files of U.S. Patent Application Serial Nos. 08/468,413 and 09/162,508 for copies of the above-listed references. Applicants will supply copies on request.

Pursuant to 37 C.F.R. § 1.98(a)(3), Applicants herein note that reference AF (publication DE 4321944 A1) is a foreign language publication which was cited to the Applicants in a Supplemental European Search Report (reference AO). Applicants also note that reference AF (publication DE 4321944 A1) was cited as a priority document in reference AP (PCT publication WO 95/00851). Applicants herein respectfully refer the Examiner to the English language abstract in reference AP for a concise explanation of reference AF.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 9, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: 301-251-6015

JKE/DAS/lc/kp